AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Products / Anti-nerve agents

Anti-nerve agents

March 15, 2017 By antoxa

Butyrylcholinesterase (BuChE) to protect against nerve agents

AntoXa and the Government of Canada are co-developing butyrylcholinesterase (BuChE) as a next-generation therapeutic and prophylactic countermeasure to organophosphate toxins such as sarin and soman.

BuChE is a naturally occurring plasma enzyme that provides broad-spectrum protection against all nerve agents. Purified human BuChE has been proven efficacious in animal models; however, its development has been limited by relatively low production yield compared to very high cost as well as the inherent risk of human pathogen transmission from the plasma derived product. AntoXa has produced a high-yield, low-cost recombinant BuChE using the vivoXPRESS® platform and successfully evaluated the safety of the product in an animal model.

Filed Under: Products

Latest News

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

Ron Hosking appointed to AntoXa Corporation Board of Directors

November 28, 2018

Guelph, Ont., Canada, Nov. 28, 2018 — Ron Hosking, CPA, CA, has been ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2019 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates